Literature DB >> 16891649

Mini-incision for strictly retroperitoneal nephrectomy in living kidney donation vs flank incision.

A A Schnitzbauer1, M Loss, M Hornung, G Glockzin, L Mantouvalou, B Krüger, B K Krämer, H J Schlitt, A Obed.   

Abstract

BACKGROUND: Mini-incision donor nephrectomies (MIDNs) were established during the last decade, as an alternative to traditional open donor nephrectomy (ODN) via flank incision. In this study, we investigated intra-operative and post-operative data on outcome following MIDN in comparison with ODN data.
METHODS: Data of 70 living kidney donations, performed at the University of Regensburg Medical Center since 1996, were evaluated. Donor operation was performed as either strictly retroperitoneal MIDN (n = 34) or as traditional ODN (n = 36) via flank incision. Total operation time, warm ischaemia time (WIT), perioperative pain-medication usage and creatinine levels as well as length of hospital stay, return to complete enteral nutrition and regular digestion were evaluated retrospectively.
RESULTS: Total operation times were similar in MIDN, n = 34 (132 +/- 26 min) and in ODN, n = 36 (140 +/- 37 min) (P = 0.424). WIT was also similar in both: MIDN (0.9 +/- 0.4 min) and ODN (0.9 +/- 0.4 min) (P = 0.568). The requirement for post-operative opioids in morphine equivalent doses was significantly lower in MIDN (8.4 +/- 16 mg) compared with ODN (44 +/- 57 mg) (P = 0.001). Additional application of non-opioids (metamizole) (MIDN: 4.8 +/- 6.3 g, ODN: 3.4 +/- 3.9 g) and non-steroidal antirheumatic (NSAR) (diclofenac) (MIDN: 322 +/- 361 mg, ODN: 247 +/- 474 mg) revealed no significant differences between the groups. The hospital stay was 4.9 +/- 1.4 days in MIDN which was significantly shorter than that in ODN (9.3 +/- 3.3 days) (P = 0.001). Patients achieved fully independent mobility earlier in MIDN than in ODN (P = 0.934). Start of enteral nutrition with fluids was significantly quicker in MIDN (1.9 +/- 7 h) compared with ODN (12 +/- 13 h) (P = 0.05). Full enteral nutrition was accomplished significantly earlier in MIDN (1.6 +/- 0.8 days) (P = 0.023). Return to normal digestion revealed no significant differences between groups. Serum creatinine levels of all kidney donors were in the normal range (66 +/- 18 micromol/l) one day before nephrectomy, increased on day 1 after surgery (119 micromol/l +/- 31 micromol/l) and were stable on day 3 (115 micromol/l +/- 30 micromol/l) without significant differences.
CONCLUSION: Strictly, retroperitoneal MIDN in living kidney donation is a fast and safe method for the procurement of a living donor graft, giving the patient a significantly shorter period of recovery, and thus is an attractive and recommendable alternative to traditional ODN procedures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891649     DOI: 10.1093/ndt/gfl158

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  Donor Nephrectomy Through Mini-Flank Incision: A Single-Centre Experience Among Nigerian Patients.

Authors:  Martin C Igbokwe; Olalekan O Olatise; Stephen O Asaolu; Abayomi A Aremu; Sadiq Abu; Uzodinma Onwuasoanya; Adefola R Adetunbi; Sani Alhassan
Journal:  Cureus       Date:  2022-05-22

2.  The mini-incision donor nephrectomy is best suited for Indian patients undergoing live donor nephrectomy: against the motion.

Authors:  Pranjal Modi
Journal:  Indian J Urol       Date:  2010 Jan-Mar

3.  Surgical complications of open nephrectomy in living related donors in Yemen: a prospective study.

Authors:  Khaled Abdulla Telha; Mohamed Abdullah Al Kataa; Khaled Mohamed Al-Kohlany; Tawfik Hassen Al Badany; Ibrahim Hussen Alnono
Journal:  Turk J Urol       Date:  2017-12-01

4.  Approach via a small retroperitoneal anterior subcostal incision in the supine position for gasless laparoendoscopic single-port radical nephrectomy: initial experience of 42 patients.

Authors:  Tatsuo Morita; Akira Fujisaki; Taro Kubo; Shinsuke Kurokawa
Journal:  BMC Urol       Date:  2014-04-04       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.